Zogenix, Inc. (ZGNX): Price and Financial Metrics
ZGNX Stock Summary
- ZGNX's price/sales ratio is 84.12; that's higher than the P/S ratio of 96.13% of US stocks.
- With a year-over-year growth in debt of 1,236.38%, Zogenix Inc's debt growth rate surpasses 98.6% of about US stocks.
- Revenue growth over the past 12 months for Zogenix Inc comes in at 273.99%, a number that bests 97.38% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Zogenix Inc, a group of peers worth examining would be BCYC, DSPG, NPTN, MYOV, and CDXS.
- ZGNX's SEC filings can be seen here. And to visit Zogenix Inc's official web site, go to www.zogenix.com.
ZGNX Stock Price Chart Interactive Chart >
ZGNX Price/Volume Stats
|Current price||$20.26||52-week high||$32.42|
|Prev. close||$20.59||52-week low||$16.65|
|Day high||$20.84||Avg. volume||947,720|
|50-day MA||$20.66||Dividend yield||N/A|
|200-day MA||$23.11||Market Cap||1.13B|
Zogenix, Inc. (ZGNX) Company Bio
Zogenix develops and commercializes therapies for the treatment of central nervous system disorders. The company was founded in 2006 and is based in San Diego, California.
ZGNX Latest News Stream
|Loading, please wait...|
ZGNX Latest Social Stream
View Full ZGNX Social Stream
Latest ZGNX News From Around the Web
Below are the latest news stories about Zogenix Inc that investors may wish to consider to help them evaluate ZGNX as an investment opportunity.
EMERYVILLE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will present a corporate overview and participate in a fireside chat on Wednesday, March 3, 2021, at the Raymond James Institutional Investors Conference. Zogenix Presentation DetailsDate:Wednesday, March 3, 2021Time: 3:50 PM Eastern Time The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com. About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the ...
Zogenix (NASDAQ:ZGNX) announced its earnings results on Thursday. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.21), MarketWatch Earnings reports. Zogenix had a negative return on equity of 53.91% and a negative net margin of 8,758.48%. ZGNX stock traded down $0.92 on Friday, hitting $21.24. 35,401 […]
EMERYVILLE, Calif. (AP) _ Zogenix Inc. (ZGNX) on Thursday reported a loss of $70.2…
In this article, we will discuss the 15 Best Micro-Cap Stocks to Buy Now. You can skip our discussion of the merits of investing in micro-cap stocks and go directly to 5 Best Micro-Cap Stocks to Buy Now. A micro-cap stock has a market capitalization between $50 million to $1 billion. Micro-cap stocks have higher […]
Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25
EMERYVILLE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2020 and host a corporate update conference call and webcast after the market close, on Thursday, February 25, 2021, at 4:30 PM Eastern Time. Conference Call DetailsThursday, February 25, at 4:30 PM Eastern Time / 1:30 PM Pacific TimeToll Free:877-407-9716International:201-493-6779Conference ID:13715661Webcast:http://public.viavid.com/index.php?id=143250 About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their f...
ZGNX Price Returns
Continue Researching ZGNXWant to see what other sources are saying about Zogenix Inc's financials and stock price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!